Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $418458.0.

  • Lipocine's Change in Account Payables rose 35601.43% to $418458.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $576105.0, marking a year-over-year increase of 17062.53%. This contributed to the annual value of -$1.1 million for FY2024, which is 24131.43% down from last year.
  • Latest data reveals that Lipocine reported Change in Account Payables of $418458.0 as of Q3 2025, which was up 35601.43% from $82755.0 recorded in Q2 2025.
  • In the past 5 years, Lipocine's Change in Account Payables ranged from a high of $583481.0 in Q3 2023 and a low of -$1.0 million during Q1 2021
  • In the last 5 years, Lipocine's Change in Account Payables had a median value of -$13651.0 in 2024 and averaged -$38724.6.
  • In the last 5 years, Lipocine's Change in Account Payables soared by 108080.68% in 2023 and then tumbled by 46949.33% in 2024.
  • Quarter analysis of 5 years shows Lipocine's Change in Account Payables stood at $563790.0 in 2021, then plummeted by 105.33% to -$30068.0 in 2022, then skyrocketed by 1080.81% to $294909.0 in 2023, then tumbled by 104.63% to -$13651.0 in 2024, then soared by 3165.4% to $418458.0 in 2025.
  • Its last three reported values are $418458.0 in Q3 2025, $82755.0 for Q2 2025, and $88543.0 during Q1 2025.